NFKB1 and Alzheimer disease: By comparing core signaling pathways and their downstream cellular dysfunctions in AD and healthy controls to investigate the pathogenetic mechanisms of AD, as shown in Figure 4, we identified IL-1β, GATA3, Akt, and NF-κB as the drug targets (biomarkers).